



## PARABOLIC DRUGS LIMITED

# Parabolic Drugs gets Japanese nod for Cephalosporin Drugs Receives Accreditation as a Foreign Drugs manufacturer from Japanese PMDA

### Japanese Accreditation

BSE Code: 533211  
NSE Code: PARABDRUGS

---

FY11 Sales: Rs. 675.30 crore  
5 year CAGR: 41.84%  
FY11 Net Profit: Rs. 52.87 crore  
5 year CAGR: 39.71%

---

Headquartered in Chandigarh, with 3 manufacturing facilities – two in Punjab and one in Haryana; a world-class custom synthesis and R&D centre at Barwala, (Haryana)

---

1200+ employees including R&D Team of 100 Scientists

---

Product portfolio comprising of 44 APIs and 7 API intermediates; filed 38 Drug Master Files

---

Aiming to emerge as a Global Pharmaceuticals Company by 2015

### For more information:

Sameer Madan  
Vice President- Trade Finance  
Parabolic Drugs, Chandigarh  
[sameer.madan@parabolicdrugs.com](mailto:sameer.madan@parabolicdrugs.com)  
+ 91 172 391 4658

Parthajeet Sarmah  
Christensen  
[psarmah@christensenir.com](mailto:psarmah@christensenir.com)  
+91 98670 01356

*Mumbai, October 24, 2011:* Parabolic Drugs Ltd., a vertically integrated API manufacturer and exporter in India, today announced that it has received an official accreditation from Japan's ministry of Health, Labour and Welfare, enabling it to manufacture and supply Cephalosporin non sterile drugs to the Japanese market.

The 5-year accreditation has been awarded to PDL's manufacturing site at Derabassi in Punjab and is in accordance with Article 13-3 of the *Pharmaceutical Affairs Act*, which classifies Parabolic Drugs as a certified foreign drug manufacturer.

Japan, the second single largest drug market in the world is also a leading nation in terms of pharma research, technology, machinery and medical research and is valued at USD 107 billion in 2010. The Japanese certification denotes the company's technical capability in the non-sterile market and also differentiates it from many of its competitors.

The EU GMP accredited Derabassi facility is a dedicated Cephalosporin manufacturing site that is spread across 27 Acres and has an annual capacity over 900 Tons of Cephalosporin. This accreditation is an essential element of Company's regulatory market vision as the Japanese market is an arena it hopes to heighten its market presence.

The company sees an opportunity in building its regulated market business in the \$21 Billion Global Cephalosporin Molecule market and has over 38 DMFs filed across EU, Canada and USA. It also has over 3 molecules in pipeline for filing it in Japan. In the FY 11, the company's exports accounted for 36.98% of the total revenues, with direct exports alone accounting to 28.21%.

### About Parabolic Drugs Ltd.

Parabolic Drugs Ltd., incorporated in 1996, is promoted by professionally qualified first generation entrepreneurs. It is engaged in manufacturing, including contract manufacturing, of APIs and API intermediates for domestic and international markets, including regulated markets. It manufactures Semi Synthetic Penicillin ("SSP") and Cephalosporin range of antibiotics, whereby the product portfolio comprises 44 APIs and 7 API intermediates. The company has three manufacturing facilities located across Punjab and Haryana. It also has a custom synthesis and R&D centre at Barwala, Haryana, which started operations in January 2010.